| 2021-01-18 | class updated from VUS to disease-causing |
Variant NM_000492.4:c.346G>A
| Name | NM_000492.4:c.346G>A |
| Protein name | NP_000483.3:p.(Glu116Lys) |
| Genomic name (hg19) | chr7:g.117171025G>A UCSC |
| Genomic name (hg38) | chr7:g.117530971G>A UCSC |
| #Exon/intron | exon 4 |
| Legacy Name | E116K |
| Class | disease-causing |
| WT sequence | TTCCTATGACCCGGATAACAAGGAG G AACGCTCTATCGCGATTTATCTAGG |
| Mutant sequence | TTCCTATGACCCGGATAACAAGGAG A AACGCTCTATCGCGATTTATCTAGG |
![]() |
![]() | dbSNP rs397508571 |
![]() | ![]() |
| Reference | PMID | Splicing | mRNA level | Maturation | Localization | Channel fonction (Cl-) | Bicarbonate |
| Hammerle et al, 2001 | 11278813 | ✓ | ✓ | ✓ |
« ✓ » indicates the type of analysis performed and not the results
| Modulator | FDA approval | EMA approval | in vitro / ex vivo data | clinical data |
| IVA | no | no | no | no |
| TEZ-IVA | yes | no | yes | no |
| ELX-TEZ-IVA | yes | no | yes | no |
| VNZ-TEZ-DIVA | yes | no | yes | no |
clinical and functional data presented above are provided by Vertex
No patient found in CFTR-NGS catalogue |
| TOTAL NUMBER OF PATIENTS | 2 |
|---|---|
| CF | 1 |
| CFTR-RD | 1
|
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| Phenotype | Patient ID | Variant status | Additional variants |
|---|---|---|---|
| Other | 315 | heterozygote | varying clinical consequence- Undef |
| CF | 1018 | heterozygote | CF-causing - Trans |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| CFTR variants are clustered into five groups (click here for more details about the classification of variants): |
|